Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritis
Annals of the Rheumatic Diseases · 2025
DOI: 10.1016/j.ard.2025.01.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2025. Verfasst von Viktor Molander und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Rheumatology, Theme Inflammation and Ageing, …. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Biological Products, Immunomodulating Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VINNOVA, Swedish Heart and Lung Association, Hjärt-Lungfonden.
Abstract (Originalsprache)
OBJECTIVES: To investigate rates of key safety outcomes in patients with rheumatoid arthritis (RA) initiating biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and in reference cohorts, presented over time since the market entry of each b/tsDMARD class and over calendar period at treatment start. METHODS: This was a nationwide register-based cohort study conducted from 2006 to 2022. From the Swedish Rheumatology Quality Register and national registers, we identified treatment initiators of b/tsDMARDs (n = 33,550 initiations), an early bionaive RA cohort (n = 16,011), and a matched general population cohort (n = 111,074). The main outcome was first of either major adverse cardiovascular event, venous thromboembolism, cancer, or serious infection. We stratified rates by time since market entry of each b/tsDMARD class at treatment start, and by calendar year of treatment start. We calculated incidence rates (IRs) and hazard ratios (HRs) using Cox regression and adjusted for patient characteristics. RESULTS: Overall, 5862 events were observed in the b/tsDMARD initiator cohort. b/tsDMARD treatments initiated >5 (vs
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Rheumatology, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden. Electronic address:…
- Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Rheumatology, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden.
Förderung
- VINNOVA
- Swedish Heart and Lung Association
- Hjärt-Lungfonden
- Cancerfonden
- NordForsk
- Vetenskapsrådet
Zitieren
APA
Molander, V., Bower, H., Frisell, T., & Askling, J. (2025). Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.01.020
Vancouver
Molander V, Bower H, Frisell T, Askling J. Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritis. Annals of the Rheumatic Diseases. 2025. doi:10.1016/j.ard.2025.01.020
BibTeX
@article{Molander2025,
author = {Molander, Viktor and Bower, Hannah and Frisell, Thomas and Askling, Johan},
title = {Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritis},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
doi = {10.1016/j.ard.2025.01.020}
}
EUVIMED